Bristol Myers Squibb Enhances Neuroscience Arm with Karuna Therapeutics Buyout
Bristol Myers Squibb has declared the finalization of its purchase of Karuna Therapeutics, Inc. With this acquisition concluded Karuna’s shares are no longer being traded on the Nasdaq Global Select Market, as Karuna is now fully owned by Bristol Myers Squibb.
“We are thrilled to broaden our range of neuroscience offerings with the addition of Karuna to Bristol Myers Squibb,” stated Chris Boerner, Ph.D., Chief Executive Officer of Bristol Myers Squibb. “Crucially, this agreement supports our dedication to enhancing BMS’s growth prospects for the latter part of this decade and beyond....
